Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

Intravenous BCG vaccine with a built-in kill-switch was found to be at least as effective as regular tuberculosis vaccine in ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Prime Minister Narendra Modi unveiled the genome sequencing data of 10,000 Indian nationals, marking a significant milestone ...

Researchers investigate the cellular and molecular mechanisms through which stress exacerbates immunoglobulin E cutaneous allergic inflammation.

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

In a study that could help scientists better understand and manipulate cell division, RIKEN biologists have engineered ...

BAG3 DCM is a devastating monogenic heart disease affecting more than 70,000 patients in the U.S., Europe, and U.K., with almost 25% of patients requiring a heart transplant AFTX-201 is a potential ...

In fact, from Merck's $1.3 billion deal to GSK's $850 million investment, the "gold content" of Chinese companies' self-developed TCE bispecific antibodies has already been well proven. The new moves ...